Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer

Weng, Mingjiao; Wu, Di; Yang, Chao; Peng, Haisheng; Wang, Guangyu; Wang, Tianzhen; Li, Xiaobo

doi:10.1016/j.trsl.2016.10.001

Cited by 76 publications

(46 citation statements)

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer is one of the deadliest solid malignancies, and the involvement of noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer has been widely investigated [33–35]. In addition to the aggressive properties of colorectal cancer, the lack of specific biomarkers for its diagnosis, therapeutic effect monitoring and prognosis might also be responsible for the low survival rate.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Zeng

Liang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Growing evidence has shown that long non-coding RNAs (lncRNAs) can serve as prospective markers for survival in patients with colorectal adenocarcinoma. However, most studies have explored a limited number of lncRNAs in a small number of cases. The objective of this study is to identify a panel of lncRNA signature that could evaluate the prognosis in colorectal adenocarcinoma based on the data from The Cancer Genome Atlas (TCGA). Altogether, 371 colon adenocarcinoma (COAD) patients with complete clinical data were included in our study as the test cohort. A total of 578 differentially expressed lncRNAs (DELs) were observed, among which 20 lncRNAs closely related to overall survival (OS) in COAD patients were identified using a Cox proportional regression model. A risk score formula was developed to assess the prognostic value of the lncRNA signature in COAD with four lncRNAs (LINC01555, RP11-610P16.1, RP11-108K3.1 and LINC01207), which were identified to possess the most remarkable correlation with OS in COAD patients. COAD patients with a high-risk score had poorer OS than those with a low-risk score. The multivariate Cox regression analyses confirmed that the four-lncRNA signature could function as an independent prognostic indicator for COAD patients, which was largely mirrored in the validating cohort with rectal adenocarcinoma (READ) containing 158 cases. In addition, the correlative genes of LINC01555 and LINC01207 were enriched in the cAMP signaling and mucin type O-Glycan biosynthesis pathways. With further validation in the future, our study indicates that the four-lncRNA signature could serve as an independent biomarker for survival of colorectal adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Zeng

Liang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…LncRNAs function at every level of gene regulation [125, 126], and are implicated in many different pathoses ranging from autoimmunity to cancer [127, 128]. LncRNAs regulate many aspects of innate immunity including cytokine and chemokine expression, apoptosis, and antigen presentation [129].…”

Section: Mechanisms Of Innate Immune Activation In Ssmentioning

confidence: 99%

Innate immunity in Sjögren's syndrome

Kiripolsky

McCabe

Kramer

2017

Clinical Immunology

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is an autoimmune disease of exocrine tissue that primarily affects women. Although patients typically experience xerostomia and xerophthalmia, numerous systemic disease manifestations are seen. Innate immune hyperactivity is integral to many autoimmune diseases, including SS. Results from SS mouse models suggest that innate immune dysregulation drives disease and this is a seminal event in SS pathogenesis. Findings in SS patients corroborate those in mouse models, as innate immune cells and pathways are dysregulated both in exocrine tissue and in peripheral blood. We will review the role of the innate immune system in SS pathogenesis. We will discuss the etiology of SS with an emphasis on innate immune dysfunction. Moreover, we will review the innate cells that mediate inflammation in SS, the pathways implicated in disease, and the potential mechanisms governing their dysregulation. Finally, we will discuss emerging therapeutic approaches to target dysregulated innate immune signaling in SS.

show abstract

“…In eukaryotic cells, a number of lncRNAs have been shown to regulate DNA modifications, RNA transcription, pre-mRNA splicing, mRNA degradation, and mRNA translation, in addition to other functions that influence genetic and epigenetic expression levels [24,25]. Functions of many lncRNAs are linked with cancers that nonexclusively include those originating in the colon, lung, breast, stomach, and connective tissue [26,27,28,29,30]. Dysregulation of lncRNAs can influence metastasis, chemosensitivity, and tumor cell growth and proliferation [31,32,33,34].…”

Section: Introductionmentioning

confidence: 99%

Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets

Garbutt

et al. 2017

IJMS

View full text Add to dashboard Cite

Sarcoma includes some of the most heterogeneous tumors, which make the diagnosis, prognosis and treatment of these rare yet diverse neoplasms especially challenging. Long noncoding RNAs (lncRNAs) are important regulators of cancer initiation and progression, which implies their potential as neoteric prognostic and diagnostic markers in cancer, including sarcoma. A relationship between lncRNAs and sarcoma pathogenesis and progression is emerging. Recent studies demonstrate that lncRNAs influence sarcoma cell proliferation, metastasis, and drug resistance. Additionally, lncRNA expression profiles are predictive of sarcoma prognosis. In this review, we summarize contemporary advances in the research of lncRNA biogenesis and functions in sarcoma. We also highlight the potential for lncRNAs to become innovative diagnostic and prognostic biomarkers as well as therapeutic targets in sarcoma.

show abstract

Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer

Cited by 76 publications

References 152 publications

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Comprehensive investigation of a novel differentially expressed lncRNA expression profile signature to assess the survival of patients with colorectal adenocarcinoma

Innate immunity in Sjögren's syndrome

Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets

Contact Info

Product

Resources

About